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Department of Microbiology, University Hospital Virgen Macarena, Seville, Spain1; Department of Microbiology, School of
Medicine, University of Seville, Seville, Spain2; and Department of Internal Medicine,
University Hospital Virgen Macarena, Seville, Spain3
Received 24 October 2007/Returned for modification 13 December 2007/Accepted 9 February 2008
The fatal outcome of levofloxacin treatment in a patient with bacteremic pneumonia caused by Streptococcus
pneumoniae with a preexisting parC mutation is reported. Failure was due to the emergence of a gyrA mutation
after 4 days of therapy. Problems encountered in detecting first-step mutation isolates are discussed.
CASE REPORTS
A 79-year-old man with a history of chronic obstructive lung
disease, hypertension, and transient ischemic attacks with re-
sidual dysarthria and right hemiparesis, was admitted to the
emergency room with abrupt-onset fever, increased coughing,
and dyspnea. On admission, the patient’s temperature was
38.6°C and his white blood cell count was 18,000/l (88.2%
neutrophils). Arterial gasometry showed pH  7.48, pO2  59
mm Hg, and pCO2  41 mm Hg, and chest radiography re-
vealed condensation in the lower right lobe. The patient was
hospitalized with a diagnosis of community-acquired pneumo-
nia (CAP).
Blood cultures were taken before commencing empirical
treatment with levofloxacin (500 mg [given intravenously]/24
h). At 24 h, growth of gram-positive cocci arranged in pairs was
observed in the blood culture bottles. After subculturing, the
microorganism was identified as Streptococcus pneumoniae sus-
ceptible to penicillin (Etest MIC, 0.06 g/ml) and levofloxacin
(Etest MIC, 1 g/ml).
In view of the susceptibility results and because the patient’s
condition showed some clinical improvement (decrease in fe-
ver and total leukocyte number), treatment continued with
levofloxacin at the same dosage. However, the fever reap-
peared on day 4 of hospitalization with the patient showing
hypotension and tachycardia. A further blood culture was ob-
tained, and it was decided to change the treatment to intrave-
nous amoxicillin (1 g/8 h). The patient’s clinical condition
failed to improve, and he died in the hospital on day 5.
The S. pneumoniae isolate grown in the second blood culture
was susceptible to penicillin (E-test MIC, 0.06 g/ml) and
resistant to levofloxacin (E-test MIC, 32 g/ml). Both iso-
lates were susceptible to trimethoprim-sulfamethoxazole, tet-
racycline, vancomycin, erythromycin, and clindamycin. No
changes in the MICs were observed.
S. pneumoniae is the most common bacterial pathogen in
CAP. The emergent resistance of these isolates to beta-lactams
and macrolides has caused some concern about their use in the
empirical treatment of CAP (11). Fluoroquinolones such as
levofloxacin, with increased activity against S. pneumoniae, are
now recommended for the empirical treatment of this infection
(11, 13). The rate of fluoroquinolone-resistant S. pneumoniae
infection remains low in most parts of the world, although an
increase in fluoroquinolone use also implies a greater risk that
resistant isolates will appear (10). Resistance to newer fluoro-
quinolones in S. pneumoniae may be emerging as a result of
their increased use. In Spain, the reported resistance rate rose
from 0.9% in the 1990s to 7.1% after the year 2000 (6, 14, 15),
and significant increases have been noted in other countries
such as the United States (7) and Canada (1). Higher rates of
quinolone resistance have been found in isolates from the
respiratory tracts of adult patients (14, 15).
Fluoroquinolone resistance in pneumococci has been re-
ported previously as a cause of treatment failure, although in
only a few cases has an in vivo selection for resistance been
demonstrated (3, 8, 15). We describe here the emergence of a
gyrA mutation and failure of levofloxacin treatment leading to
death in a patient with bacteremic CAP caused by S. pneu-
moniae with a preexisting parC mutation.
Fluoroquinolone resistance in S. pneumoniae is the result of
target mutations in the quinolone resistance-determining re-
gions (QRDRs) of parC and gyrA, which encode topoisomer-
ase IV and DNA gyrase, respectively (1, 10, 18). Low-level
resistance occurs after a first-step mutation in one of the target
genes, and high-level resistance occurs after a subsequent mu-
tation in the other one. Isolates with a single first-step parC
mutation are frequently susceptible to fluoroquinolones be-
cause the MICs are at or below the Clinical and Laboratory
Standards Institute (CLSI) breakpoints (4). However, a first-
step parC mutation increases the likelihood of a subsequent
gyrA mutation, high-level resistance, and therapeutic failure (1,
18). At the same time, it has also been observed that once a
parC mutation has taken place in an S. pneumoniae strain, the
mutation prevention concentration (MPC) increases dramati-
cally for all fluoroquinolones (17). Reports by Croisier et al.
and Allen et al. showed that after levofloxacin or moxifloxacin
treatment, mutants occur in vivo if there is a preexisting parC
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mutation since the drug concentrations fall below the MPCs of
the strains. Increasing both the drug concentration and expo-
sure to exceed the MPC may prevent mutant strains from
emerging, although this strategy did not prevent the selec-
tion of secondary mutants in strains with preexisting muta-
tions (2, 5).
According to the recommendations of the CLSI, levofloxa-
cin susceptibility in S. pneumoniae is defined as a MIC of 2
g/ml (4). This breakpoint, however, only allows the detection
of high-level resistant mutants affecting at least two targets;
the prevalence of pneumococci which are not fluoroquin-
olone susceptible may therefore be underestimated when
the present CLSI breakpoints are used. This case report
provides disturbing evidence that fluoroquinolone-resistant
pneumococci are able to emerge within only a few days of
the start of treatment.
Both of the blood culture isolates belonged to serotype 8 (a
non-seven-valent vaccine serotype), and their clonal relation-
ship was demonstrated by pulsed-field gel electrophoresis
(PFGE) (Fig. 1) with the SmaI endonuclease (6). By PCR and
sequencing (12), the first isolate showed a mutation in the
QRDR of parC (Ser79Phe), and the second one had an addi-
tional gyrA mutation (Ser81Phe). These mutations are most
commonly found in fluoroquinolone-resistant S. pneumoniae
strains (1, 18). In addition, genetic relatedness was supported
by several polymorphisms identified in the QRDRs of the two
isolates: Met1Leu in parC and Ile460Val in parE. Using PCR,
we investigated the presence of the qnrA, qnrB, and qnrS genes
that cause plasmid-mediated quinolone resistance in gram-
negative rods (16). The result was negative for both isolates.
There is no currently available test for accurately identifying
isolates with low-level fluoroquinolone resistance. In common
with other authors, we consider it an urgent task to develop a
phenotypic test which will permit the accurate detection of
first-step mutants associated with treatment failure in some
pneumonia cases.
The Comité de l’Antibiogramme of the Societé Française de
Microbiologie (CA-SFM) recommends the use of norfloxacin,
similar to the use of the oxacillin disk test, as a marker for
detecting low-level fluoroquinolone-resistant pneumococci.
According to the CA-SFM, when the inhibition zone around a
disk containing 5 g of norfloxacin is 10 mm or the MIC is
16 g/ml, the risk of “in vivo” selection of fluoroquinolone-
resistant mutants and of therapeutic failure is high (CA-SFM
[http://www.sfm.asso.fr/publi/general.php?pa1]).
Another proposed screening test is the MIC for ciprofloxa-
cin, where an MIC of 4 g/ml defines nonsusceptible isolates.
However, about 30% of the isolates in the susceptible category
harbor first-step mutations (10).
A number of risk factors have been identified as identifying
patients who are likely to be colonized or infected with fluo-
roquinolone-resistant pneumococci, i.e., patients who are 64
years of age and have a history of chronic obstructive lung
disease and/or prior fluoroquinolone exposure (9). In our case,
we do no know whether the patient had previously received
fluoroquinolone treatment. However, the risk factors associ-
ated with infections caused by first-step quinolone-resistant S.
pneumoniae mutants remain to be studied so that future re-
search into the effects of these factors may well determine the
full clinical implications of this trend.
Because currently available phenotypic diagnostic tests are
unable to identify pneumococci with a first-step mutation, em-
pirical monotherapy using fluoroquinolones may be inappro-
priate for patients with CAP whose risk factors include infec-
tion with fluoroquinolone-resistant pneumococci.
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3. Carlavilla, A. B., F. López-Medrano, F. Chaves, V. Villena, J. Echave-Sus-
taeta, and J. M. Aguado. 2005. Failure of levofloxacin therapy in two cases
of community-acquired pneumonia caused by fluoroquinolone-resistant
Streptococcus pneumoniae and complicated with emphysema. Enferm. In-
fecc. Microbiol. Clin. 23:270–273.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards
for antimicrobial susceptibility testing. Fifteenth informational supplement.
M-100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Croisier, D., M. Etienne, E. Bergoin, P. E. Charles, C. Lequeu, L. Piroth, H.
Portier, and P. Chavanet. 2004. Mutant selection window in levofloxacin and
moxifloxacin treatments of experimental pneumococcal pneumonia in a rab-
bit model of human therapy. Antimicrob. Agents Chemother. 48:1699–1707.
FIG. 1. PFGE of S. pneumoniae isolates. Lane M, molecular weight
marker; lane 1, levofloxacin-susceptible S. pneumoniae (MIC  1 g/
ml); lane 2, levofloxacin-resistant S. pneumoniae (MIC, 32 g/ml);
lane 3, unrelated clone.
VOL. 46, 2008 CASE REPORTS 1559




























6. de la Campa, A. G., L. Balsalobre, C. Ardanuy, A. Fenol, E. Pérez-Trallero,
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